In 2023 and early 2024, it felt like a new GLP-1 telehealth provider launched every week. Low barriers to entry, massive consumer demand, and the semaglutide/tirzepatide shortages created a gold rush atmosphere. By mid-2024, there were hundreds of companies offering compounded GLP-1 medications online.
By early 2026, the landscape looks completely different. A series of regulatory, legal, and market forces compressed the field dramatically. What’s left is a smaller, more professional, and more trustworthy market.
What Caused the Shakeout
1. FDA Shortage Resolutions
The legal basis for most compounded GLP-1 production was the drug shortage exception under the FD&C Act. When the FDA declared the tirzepatide shortage resolved in October 2024 and the semaglutide shortage resolved in February 2025, the legal ground shifted under every provider selling these products.
Providers that had been operating under the shortage exception suddenly needed alternative legal justifications—or they needed to stop. Many couldn’t adapt quickly enough and shut down their GLP-1 programs entirely.
2. FDA Enforcement Actions
The FDA didn’t just resolve shortages—they followed up with enforcement. Warning letters went out to pharmacies that continued compounding without proper legal authority. Some faced injunctions. The 503A enforcement deadline (April 22, 2025) and 503B enforcement deadline (May 22, 2025) created hard cutoff points that forced non-compliant operations to cease.
3. FTC Actions Against Deceptive Practices
The Federal Trade Commission targeted telehealth providers using deceptive marketing practices, subscription traps, and misleading efficacy claims. The FTC’s enforcement actions sent a clear signal that fly-by-night operations would face consequences beyond just FDA scrutiny.
4. Hims & Hers vs. FDA Lawsuit
When Hims & Hers—one of the largest telehealth platforms—sued the FDA over the semaglutide shortage resolution, it spotlighted the entire regulatory battle. Regardless of the lawsuit’s outcome, the legal uncertainty it created made smaller providers nervous. Some exited the market simply because the regulatory risk wasn’t worth the investment.
5. Market Economics
As brand-name manufacturers responded to competition with savings programs, price cuts (Eli Lilly launched direct-to-consumer vials at reduced prices), and expanded insurance coverage, the price advantage of compounded medications narrowed for some patient segments. Providers with thin margins or high customer acquisition costs became unprofitable.
The Silver Lining
Market consolidation is often painful, but it’s producing a better outcome for patients. The providers that survived invested in compliance, quality pharmacy partnerships, and genuine medical oversight. The ones that didn’t are gone.
What the Survivors Have in Common
The providers still operating in 2026 share several characteristics:
- Strong pharmacy partnerships: They work with established, licensed 503A or 503B pharmacies that have LegitScript certification and (often) PCAB accreditation
- Real medical oversight: They employ or contract with licensed prescribers who conduct meaningful evaluations—not rubber-stamp questionnaires
- Regulatory flexibility: They adapted to the post-shortage landscape by pivoting to compliant formulations (like semaglutide sodium) or securing legal standing through their 503B partnerships
- Transparent business models: They publish pricing clearly, don’t use subscription traps, and make cancellation straightforward
- Patient support infrastructure: They offer ongoing care coordination, dose adjustment support, and accessible customer service
Categories of Survivors
Large Platforms
Companies like Hims & Hers, Ro, and similar large-scale telehealth platforms had the resources to fight regulatory battles, absorb legal costs, and pivot their product offerings. They also had diversified revenue streams (men’s health, women’s health, dermatology) that cushioned the GLP-1-specific volatility.
Specialized GLP-1 Providers
A second tier of providers focused exclusively or primarily on weight management. Those that survived typically had strong clinical leadership, established pharmacy relationships, and a patient-first model that generated loyalty and word-of-mouth referrals. These providers tend to offer more personalized care and closer follow-up than the large platforms.
Pharmacy-Direct Models
Some 503B outsourcing facilities built their own direct-to-patient channels, cutting out the telehealth middleman. These pharmacy-direct models offer some of the lowest prices in the market because they eliminate the margin that telehealth platforms typically add.
What This Means for You as a Patient
If you’re shopping for a GLP-1 provider in 2026, the good news is that the floor has risen. The worst operators are gone. But “still standing” doesn’t automatically mean “best choice.” Use the consolidation as a starting filter, then apply the standard vetting criteria:
- Verify the pharmacy (state license, LegitScript, 503A/503B classification)
- Confirm real medical evaluation before prescribing
- Understand total monthly cost (medication + consultation + shipping)
- Check cancellation policies and contract terms
- Look for ongoing support (follow-ups, dose adjustments, side effect management)
Looking Ahead
The market will continue evolving. Canadian generic semaglutide is expected to launch in 2026, which will add another price-competitive option. And as more clinical data on compounded formulations becomes available, the regulatory picture may shift again. The providers best positioned are those with flexible operations and strong compliance foundations.
The Bottom Line
The GLP-1 telehealth shakeout was a healthy correction. It removed bad actors, raised quality standards, and forced surviving providers to invest in the things that matter most: pharmacy quality, medical oversight, and patient support. The market in 2026 is smaller but significantly better. Your job as a patient is easier now—just make sure you’re choosing from the providers who earned their place.